| Literature DB >> 33062837 |
Abstract
OBJECTIVE: This study is addressing the question of whether a telenursing system using information and communication technology is effective for improving postoperative complications and quality of life (QOL) in patients with prostate cancer.Entities:
Keywords: Postoperative complications; prostate cancer; quality of life; telenursing
Year: 2020 PMID: 33062837 PMCID: PMC7529028 DOI: 10.4103/apjon.apjon_28_20
Source DB: PubMed Journal: Asia Pac J Oncol Nurs ISSN: 2347-5625
Figure 1Telenursing system aiming to prevent postsurgical complications and improve quality of life among patients with prostate cancer
Overview of the study participants (n=30)
| Item | |
|---|---|
| Age, mean±SD | 62.7±4.1 |
| 50 s | 9 (30.0) |
| 60 s | 21 (70.0) |
| Occupation | 12 (40.0) |
| Educational background | |
| Junior high school | 5 (16.6) |
| High school | 18 (60.0) |
| University | 6 (20.0) |
| Other | 1 (3.4) |
| Family structure | |
| Single | 4 (13.3) |
| Couple | 17 (56.6) |
| Couple and children | 4 (13.3) |
| Three generations | 5 (16.8) |
| Anamnesis | 19 (63.3) |
| PSA (presurgery), mean±SD | 6.5±1.0 |
| Gleason score (presurgery), mean±SD | 6.9±0.6 |
| <7 | 7 (23.3) |
| 7 | 18 (60.0) |
| >7 | 5 (16.7) |
| NVB | |
| Both resection | 20 (66.6) |
| One resection | 10 (33.4) |
| PDE5 inhibitors | 3 (10.0) |
| Anticholinergic drug | 6 (20.0) |
| The login status of the telenursing system | |
| Every day (7 times a week) | 23 (76.6) |
| 5-6 times a week | 4 (13.3) |
| 2-4 times a week | 2 (6.7) |
| Once a week | 1 (3.4) |
PSA: Prostate-specific antigen; NVB: Neurovascular bundle; PDE5 inhibitors: Phosphodiesterase Type 5 inhibitors; SD: Standard deviation
Comparison between 1 month and 3 months after surgery
| Intervention ( | |||
|---|---|---|---|
| 1 month | 3 months | ||
| EPIC | |||
| Summary score | |||
| Urinary | 57.9 (43.7-70.1) | 84.7 (73.7-97.8) | 0.000 |
| Bowel | 95.6 (82.1-95.2) | 100.0 (92.3-97.5) | 0.043 |
| Sexual | 27.9 (23.1-32.7) | 28.9 (19.2-32.7) | 0.125 |
| Hormonal | 87.4 (77.3-92.7) | 93.2 (79.1-94.6) | 0.022 |
| Subscale | |||
| Urinary function | 46.0 (35.0-60.0) | 76.8 (53.2-95.0) | 0.000 |
| Urinary bother | 65.2 (46.4-82.1) | 85.7 (75.0-92.7) | 0.015 |
| Urinary incontinence | 13.5 (0.0-29.0) | 66.7 (39.5-87.5) | 0.000 |
| Urinary irritative/obstructive | 86.7 (67.8-94.6) | 96.4 (78.5-92.1) | 0.046 |
| Bowel function | 93.8 (85.7-91.8) | 100.0 (89.3-96.1) | 0.032 |
| Bowel bother | 97.4 (78.5-99.4) | 100.0 (96.4-97.8) | 0.048 |
| Sexual function | 0.0 (0.0-5.6) | 2.8 (0.0-12.0) | 0.089 |
| Sexual bother | 87.5 (75.0-100.0) | 75.0 (50.0-93.8) | 0.246 |
| Hormonal function | 76.0 (60.0-100.0) | 85.0 (60.0-98.4) | 0.004 |
| Hormonal bother | 95.8 (79.0-100.0) | 100.0 (87.5-98.7) | 0.248 |
| Stress testb | 70.2 (14.2) | 93.9 (4.8) | 0.001 |
| FACT-G | |||
| Summary score | 63.0 (45.0-79.0) | 69.0 (48.0-85.0) | 0.027 |
| Subscale | |||
| Physical well-being | 15.0 (6.0-22.0) | 19.0 (9.0-26.0) | 0.000 |
| Social/family well-being | 20.0 (11.0-25.0) | 21.0 (10.0-26.0) | 0.072 |
| Emotional well-being | 13.0 (8.0-24.0) | 17.0 (10.0-25.0) | 0.032 |
| Functional well-being | 15.0 (8.0-20.0) | 18.0 (9.0-22.0) | 0.019 |
aThe Wilcoxon test was used for comparing the scores in one and three months after surgery, bThe bladder urine volume (%) after the stress test (the bladder urine volume before the stress test as 100%) and average SD. IQR: Interquartile range; SD: Standard deviation; FACT-G: Functional Assessment of Cancer Therapy-General; EPIC: Expanded prostate cancer index composite